The median survival for patients with malignant pleural mesothelioma remains extremely
poor and there is a need for the development of more effective treatment modalities. The …

Introduction Malignant mesothelioma (MM) is an aggressive malignancy arising from the
mesothelial cells lining the pleura and other serosal membranes. It is associated with an …

Purpose Malignant pleural mesothelioma (MPM) expresses high levels of epidermal growth
factor receptor (EGFR), and preclinical studies have identified antitumor activity of EGFR …

Malignant pleural mesothelioma (MPM) is an aggressive chemotherapy-resistant cancer. Up-
regulation of epidermal growth factor receptor (EGFR) plays an important role in MPM …

Malignant pleural mesothelioma is a highly aggressive cancer with a very poor prognosis.
Although the mechanism of carcinogenesis is not fully understood, approximately 80% of …

Malignant pleural mesothelioma (MPM) is an aggressive tumor with poor prognosis, whose
exposure to asbestos fibers is the main etiology. The incidence of MPM is anticipated to …

Malignant pleural mesothelioma (MPM) is a rare malignancy with no known curative
modality. Approximately 70% of MPMs have high levels of expression of the epidermal …

BACKGROUND. We conducted a phase 2, multicenter, open‐label study of erlotinib plus
bevacizumab in patients with malignant pleural mesothelioma who had previously received …

Malignant mesothelioma, a debilitating and often fatal malignancy occurs most commonly in
patients with a history of exposure to asbestos. Majority of patients with pleural malignant …

Malignant pleural mesothelioma is an aggressive tumor of the pleura with an overall poor
prognosis. Even with surgical resection, for which only a subset of patients are eligible, long …